Cargando…
Oestradiol measurement during fulvestrant treatment for breast cancer
Biochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor positive breast cancer. However, fulvestrant may interfere with oestradiol immunoassays and confound accurate assessment in this context. We conduc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461991/ https://www.ncbi.nlm.nih.gov/pubmed/30679781 http://dx.doi.org/10.1038/s41416-019-0378-9 |
_version_ | 1783410562152005632 |
---|---|
author | Owen, Laura J. Monaghan, Phillip J. Armstrong, Anne Keevil, Brian G. Higham, Claire Salih, Zena Howell, Sacha |
author_facet | Owen, Laura J. Monaghan, Phillip J. Armstrong, Anne Keevil, Brian G. Higham, Claire Salih, Zena Howell, Sacha |
author_sort | Owen, Laura J. |
collection | PubMed |
description | Biochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor positive breast cancer. However, fulvestrant may interfere with oestradiol immunoassays and confound accurate assessment in this context. We conducted a service evaluation of two immunoassays and an LC-MS/MS assay to determine the extent of the interference. Serum oestradiol levels were analysed by two immunoassays (Siemens Centaur XP and Abbott Architect) and liquid chromatography-tandem mass spectrometry (LC/MS/MS). Immunoassay gave higher serum oestradiol results than LC-MS/MS at low concentrations, with improved analytical sensitivity demonstrated by LC-MS/MS. Cross-reactivity of fulvestrant was observed for each immunoassay. We have shown that two commonly used immunoassays do not demonstrate the required sensitivity or specificity for the measurement of oestradiol in a breast cancer population. For patients receiving fulvestrant, spurious results may be generated that could impact treatment decisions. LC-MS/MS is recommended in this setting. |
format | Online Article Text |
id | pubmed-6461991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-64619912020-01-25 Oestradiol measurement during fulvestrant treatment for breast cancer Owen, Laura J. Monaghan, Phillip J. Armstrong, Anne Keevil, Brian G. Higham, Claire Salih, Zena Howell, Sacha Br J Cancer Brief Communication Biochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor positive breast cancer. However, fulvestrant may interfere with oestradiol immunoassays and confound accurate assessment in this context. We conducted a service evaluation of two immunoassays and an LC-MS/MS assay to determine the extent of the interference. Serum oestradiol levels were analysed by two immunoassays (Siemens Centaur XP and Abbott Architect) and liquid chromatography-tandem mass spectrometry (LC/MS/MS). Immunoassay gave higher serum oestradiol results than LC-MS/MS at low concentrations, with improved analytical sensitivity demonstrated by LC-MS/MS. Cross-reactivity of fulvestrant was observed for each immunoassay. We have shown that two commonly used immunoassays do not demonstrate the required sensitivity or specificity for the measurement of oestradiol in a breast cancer population. For patients receiving fulvestrant, spurious results may be generated that could impact treatment decisions. LC-MS/MS is recommended in this setting. Nature Publishing Group UK 2019-01-25 2019-02-19 /pmc/articles/PMC6461991/ /pubmed/30679781 http://dx.doi.org/10.1038/s41416-019-0378-9 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Brief Communication Owen, Laura J. Monaghan, Phillip J. Armstrong, Anne Keevil, Brian G. Higham, Claire Salih, Zena Howell, Sacha Oestradiol measurement during fulvestrant treatment for breast cancer |
title | Oestradiol measurement during fulvestrant treatment for breast cancer |
title_full | Oestradiol measurement during fulvestrant treatment for breast cancer |
title_fullStr | Oestradiol measurement during fulvestrant treatment for breast cancer |
title_full_unstemmed | Oestradiol measurement during fulvestrant treatment for breast cancer |
title_short | Oestradiol measurement during fulvestrant treatment for breast cancer |
title_sort | oestradiol measurement during fulvestrant treatment for breast cancer |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461991/ https://www.ncbi.nlm.nih.gov/pubmed/30679781 http://dx.doi.org/10.1038/s41416-019-0378-9 |
work_keys_str_mv | AT owenlauraj oestradiolmeasurementduringfulvestranttreatmentforbreastcancer AT monaghanphillipj oestradiolmeasurementduringfulvestranttreatmentforbreastcancer AT armstronganne oestradiolmeasurementduringfulvestranttreatmentforbreastcancer AT keevilbriang oestradiolmeasurementduringfulvestranttreatmentforbreastcancer AT highamclaire oestradiolmeasurementduringfulvestranttreatmentforbreastcancer AT salihzena oestradiolmeasurementduringfulvestranttreatmentforbreastcancer AT howellsacha oestradiolmeasurementduringfulvestranttreatmentforbreastcancer |